{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:31:18Z","timestamp":1775575878173,"version":"3.50.1"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.596134","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T06:15:45Z","timestamp":1604297745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.3389","volume":"10","author":[{"given":"Ahmad I.","family":"Antar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaher K.","family":"Otrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Abou Dalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32835dd84a","article-title":"Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies","volume":"20","author":"Liu","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.003","article-title":"Role of allogeneic transplantation for FLT3\/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution","volume":"17","author":"DeZern","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2001.1.375","article-title":"Non- myeloablative transplants for malignant disease","author":"Storb","year":"2001","journal-title":"Hematol Am Soci Hematol Educ Prog"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomized phase 3 trial","volume":"13","author":"Bornhauser","year":"2012","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"449e57","DOI":"10.1053\/j.seminoncol.2008.04.015","article-title":"Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality","volume":"35","author":"Meijer","year":"2008","journal-title":"Semin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3675","article-title":"Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation","volume":"19","author":"Bosi","year":"2001","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00142-9","article-title":"Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation","volume":"25","author":"Lee","year":"2001","journal-title":"Leuk Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2017.05.009","article-title":"Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell\u00a0transplantation: Guidelines from the Francophone society of bone marrow\u00a0transplantation\u00a0and cellular therapy (SFGM-TC)","volume":"104","author":"Yafour","year":"2017","journal-title":"Bull Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.01.005","article-title":"Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions","volume":"16","author":"El Cheikh","year":"2016","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1607-y","article-title":"Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)","volume":"92","author":"Ganguly","year":"2013","journal-title":"Ann Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymph"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.168716","article-title":"et al,\u00a0Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: A retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2014.0123","article-title":"Comparison of Reduced-Intensity and Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: A Meta-Analysis","volume":"23","author":"Abdul Wahid","year":"2014","journal-title":"Stem Cells Dev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702726","article-title":"Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease","volume":"27","author":"de Lima","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4253","article-title":"Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells","volume":"169","author":"Santourlidis","year":"2002","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.64","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2461-5","article-title":"Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation","volume":"94","author":"Tschan-Plessl","year":"2015","journal-title":"Ann Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European Leukemia Net MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003566","article-title":"How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation","volume":"135","author":"Spyridonidis","year":"2020","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: Methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12336","article-title":"Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation","volume":"93","author":"Bastos-Oreiro","year":"2014","journal-title":"Eur J Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.789508","article-title":"Minimal residual disease after allogeneic stem cell transplant: A comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia","volume":"54","author":"Rossi","year":"2013","journal-title":"Leuk Lymph"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12042","article-title":"CD117-CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual disease","volume":"90","author":"Rossi","year":"2013","journal-title":"Eur J Haematol"},{"key":"B48","first-page":"1301A","article-title":"Chimerism analysis after allogeneic stem cell transplantation","volume":"90","author":"Bornhauser","year":"2005","journal-title":"Haematologica"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403212","article-title":"Evaluation of STR informativity for chimerism testing\u2013comparative analysis of 27 STR systems in 203 matched related donor recipient pairs","volume":"18","author":"Thiede","year":"2004","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/ijms17091515","article-title":"Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation","volume":"17","author":"Stahl","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.007765","article-title":"Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation","volume":"94","author":"Bornh\u00e4user","year":"2009","journal-title":"Haematologica"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.09.001","article-title":"The emerging role of measurable residual disease detection in AML in morphologic remission","volume":"56","author":"Buccisano","year":"2019","journal-title":"Semin Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00655","article-title":"MRD in AML: The Role of New Techniques","volume":"9","author":"Voso","year":"2019","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563403","article-title":"In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-017-0414-2","article-title":"The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia","volume":"10","author":"Qin","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404246","article-title":"Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples","volume":"20","author":"Cloos","year":"2006","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.033","article-title":"WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates","volume":"25","author":"Cho","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.011","article-title":"Wilms\u2019 Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation","volume":"24","author":"Rautenberg","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbmt.2017.09.001","article-title":"Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value","volume":"24","author":"Nomded\u00e9u","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoi- etic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13248","article-title":"Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia","volume":"169","author":"Oshikawa","year":"2015","journal-title":"Br J Haematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B70","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-015-0208-3","article-title":"Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome","volume":"8","author":"Han","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.31","article-title":"Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT","volume":"52","author":"El-Cheikh","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): An open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2018-99-111582","article-title":"Maintenance with 5-azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients","volume":"132","author":"Oran","year":"2018","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.011","article-title":"Tolerability and efficacy of treatment with azacytidine as prophylactic or pre-emptive therapy for myeloid neoplasms after allogeneic stem cell transplantation","volume":"20","author":"Marini","year":"2020","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.266","article-title":"5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis","volume":"45","author":"Czibere","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B81","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.clml.2014.12.005","article-title":"Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation","volume":"15","author":"Antar","year":"2015","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B82","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30680","article-title":"Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia","volume":"123","author":"Battipaglia","year":"2017","journal-title":"Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.004","article-title":"Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update","volume":"19","author":"Battipaglia","year":"2019","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2991\/chi.d.190310.001","article-title":"Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study","volume":"1","author":"Bazarbachi","year":"2019","journal-title":"Clin Hematol Int"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With\u00a0FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2018-99-113582","article-title":"Radius: A Phase 2 Randomized Trial Investigating Standard of Care \u00b1 Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML","volume":"132","author":"Maziarz","year":"2018","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am J Hematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30140","article-title":"Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis","volume":"122","author":"Deol","year":"2016","journal-title":"Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.01.013","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation","volume":"22","author":"Schiller","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.82","article-title":"Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant","volume":"52","author":"Salem","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.011","article-title":"Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib","volume":"17","author":"Sharma","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.10.002","article-title":"Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy","volume":"17","author":"Sid","year":"2017","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719882666","article-title":"Allogeneic transplant for\u00a0FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant","volume":"10","author":"Bazarbachi","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2017.06.001","article-title":"How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome","volume":"65","author":"Yafour","year":"2017","journal-title":"Curr Res Transl Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.251","article-title":"Inhibition of FLT3 in AML: a focus on sorafenib","volume":"52","author":"Antar","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell\u00a0transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow\u00a0Transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory\u00a0FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"7514","DOI":"10.1200\/JCO.2020.38.15_suppl.7514","article-title":"Long-term survivors and gilteritinib safety beyond one year in\u00a0FLT3-mutated R\/R AML: ADMIRAL trial follow-up","volume":"38","author":"Perl","year":"2020","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"TPS7075","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7075","article-title":"A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML","volume":"36","author":"Levis","year":"2018","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0347-6","article-title":"Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation","volume":"54","author":"Moukalled","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B116","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.bbmt.2019.12.608","article-title":"Hypomethylating Agents and Low-Dose Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation","volume":"26","author":"Vigil","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B117","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1182\/blood.V128.22.99.99","article-title":"A phase 2 randomized study of low dose Ara-C with or without Glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"128","author":"Cortes","year":"2016","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1186\/s12885-015-1695-x","article-title":"Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activa- tion and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia","volume":"15","author":"Al-Jamal","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.596134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T06:15:48Z","timestamp":1604297748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.596134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":120,"alternative-id":["10.3389\/fonc.2020.596134"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.596134","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"article-number":"596134"}}